A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization … (NCT02073019) | Clinical Trial Compass
CompletedPhase 1
A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers
Israel33 participantsStarted 2014-08
Plain-language summary
The purpose of this study is to determine whether BL-8040 is safe, tolerable and effective in the mobilization of Hematopoietic Stem Cells (HSC) in healthy volunteers
Who can participate
Age range18 Years – 45 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Healthy male subjects
* BMI between 18 and 30 kg/m2 and Weight ≥ 60 Kg
* Subjects must be either surgically sterilized (vasectomy), or if their partner is of childbearing potential, must use two methods of contraception, one of which must be a barrier method, from the first dose until 3 months after the last dose
* Subject is able and willing to comply with the requirements of the protocol
Exclusion Criteria:
* History of clinically significant disease
* Any illness within the 4 weeks prior to the screening examination
* Any history of alcohol and/or drug of abuse addiction and/or active / past (up to 2 years before screening) nicotine consumption
* Clinically relevant deviation from normal in the physical examination and vital signs at screening or baseline
* Clinically relevant laboratory abnormalities identified at screening or baseline
* Positive tests at screening for HIV I \& II, hepatitis B and/or hepatitis C in both parts or positive tests for Syphilis, HTLV I \& II and Nucleic Acid Test (NAT) for HIV and HBV
* Positive test for urine drugs of abuse or by anamnesis (Barbiturates, Benzodiazepines, Amphetamines, Opiates, Cocaine, Cannabinoids, Methadone, Phencyclidine, and Tricyclic Antidepressants) and/or positive alcohol blood test
* Subjects who have lost or donated in excess of 400 mL of blood within 3 months prior to Day 1 of the study